scholarly journals Association between hemagglutination inhibition antibody titers and protection against RT-PCR confirmed influenza illness in children 6−35 months of age: statistical evaluation of a correlate of protection

2021 ◽  
Author(s):  
Jasur Danier ◽  
Andrea Callegaro ◽  
Jyoti Soni ◽  
Alfoso Carmona ◽  
Pope Kosalaraska ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Hemagglutination Inhibition ◽  
H1n1 Influenza ◽  
Rt Pcr ◽  
Individual Level ◽  
Correlate Of Protection ◽  
Inhibition Antibody ◽  
Clinical Protection ◽  
Antibody Titers ◽  
H3n2 Influenza

Abstract Background Data from a randomized, controlled efficacy trial of an inactivated quadrivalent influenza vaccine in children 6−35 months of age were used to determine whether hemagglutination inhibition (HI) antibody titer against A/H1N1 and A/H3N2 is a statistical correlate of protection (CoP) for the risk of RT-PCR-confirmed influenza associated with the corresponding strain. Methods The Prentice criteria were used to statistically validate strain-specific HI antibody titer as a CoP. The probability of protection was identified using Dunning's model corresponding to a pre-specified probability of protection at an individual level. The group level protective threshold was identified using Siber's approach, leading to unbiased predicted vaccine efficacy (VE). A case-cohort sub-sample was used for this exploratory analysis. Results Prentice criteria confirmed that HI titer is a statistical CoP for RT-PCR-confirmed influenza. Dunning's model predicted a probability of protection of 49.7% against A/H1N1 influenza and 54.7% against A/H3N2 influenza at an HI antibody titer of 1:40 for the corresponding strain. Higher titers of 1:320 were associated with more than 80% probability of protection. Siber's method predicted VE of 61.0% at a threshold of 1:80 for A/H1N1 and 46.6% at 1:113 for A/H3N2. Conclusions The study validated HI antibody titer as a statistical CoP, by demonstrating that HI titer is correlated with clinical protection against RT-PCR-confirmed influenza associated with the corresponding influenza strain and is predictive of VE in children 6−35 months of age.

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

2011 ◽  
Vol 30 (12) ◽  
pp. 1081-1085 ◽  
Author(s):  
Steven Black ◽  
Uwe Nicolay ◽  
Timo Vesikari ◽  
Markus Knuf ◽  
Giuseppe Del Giudice ◽  
...  
Keyword(s):  
Hemagglutination Inhibition ◽  
Influenza Vaccines ◽  
Correlate Of Protection ◽  
Inhibition Antibody ◽  
Antibody Titers

scholarly journals Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease

2015 ◽  
Vol 2 (2) ◽  
Author(s):  
Anne Benoit ◽  
Jiri Beran ◽  
Jeanne-Marie Devaster ◽  
Meral Esen ◽  
Odile Launay ◽  
...  
Keyword(s):  
Characteristic Curve ◽  
Fold Increase ◽  
Correlate Of Protection ◽  
Pooled Data ◽  
Trivalent Influenza Vaccine ◽  
Inhibition Antibody ◽  
Antibody Titers ◽  
H3n2 Influenza ◽  
Antibody Levels ◽  
The Relationship

Background.  To investigate the relationship between hemagglutinin-inhibition (HI) antibody levels to the risk of influenza disease, we conducted a correlate of protection analysis using pooled data from previously published randomized trials. Methods.  Data on the occurrence of laboratory-confirmed influenza and HI levels pre- and postvaccination were analyzed from 4 datasets: 3 datasets included subjects aged <65 years who received inactivated trivalent influenza vaccine (TIV) or placebo, and 1 dataset included subjects aged ≥65 years who received AS03-adjuvanted TIV (AS03-TIV) or TIV. A logistic model was used to evaluate the relationship between the postvaccination titer of A/H3N2 HI antibodies and occurrence of A/H3N2 disease. We then built a receiver-operating characteristic curve to ide.jpegy a potential cutoff titer between protection and no protection. Results.  The baseline odds ratio of A/H3N2 disease was higher for subjects aged ≥65 years than <65 years and higher in seasons of strong epidemic intensity than moderate or low intensity. Including age and epidemic intensity as covariates, a 4-fold increase in titer was associated with a 2-fold decrease in the risk of A/H3N2 disease. Conclusions.  The modeling exercise confirmed a relationship between A/H3N2 disease and HI responses, but it did not allow an evaluation of the predictive power of the HI response.

scholarly journals Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection

2011 ◽  
Vol 204 (12) ◽  
pp. 1879-1885 ◽  
Author(s):  
Suzanne E. Ohmit ◽  
Joshua G. Petrie ◽  
Rachel T. Cross ◽  
Emileigh Johnson ◽  
Arnold S. Monto
Keyword(s):  
Antibody Titer ◽  
Hemagglutination Inhibition ◽  
Inhibition Antibody

Early protection of puppies against canine parvovirus: a comparison of two vaccines

1997 ◽  
Vol 33 (3) ◽  
pp. 244-250 ◽  
Author(s):  
DL McCaw ◽  
D Tate ◽  
EJ Dubovi ◽  
JC Johnson
Keyword(s):  
Antibody Titer ◽  
Hemagglutination Inhibition ◽  
Canine Parvovirus ◽  
Protective Antibody ◽  
Younger Age ◽  
Antibody Titers ◽  
To Receive

Client-owned puppies randomly were assigned to receive one of two commercially available polyvalent vaccines. The response to the parvovirus portion of each vaccine was evaluated by determining antibody titers by hemagglutination inhibition. Significant differences were found between titers produced by the vaccines. Puppies vaccinated with one of the products had a more desirable result as demonstrated by a protective antibody titer after the first vaccination (p of 0.005), a protective antibody titer at a younger age (p of 0.02), a protective antibody titer by 12 weeks of age (p of 0.001), and a protective antibody titer by 16 weeks of age (p of 0.05). Puppies vaccinated with this product also had significantly higher titers at each sampling after vaccination.

scholarly journals Characteristics of convalescent plasma donors and their antibody titers in Bangladesh

2021 ◽  
Vol 8 (4) ◽  
pp. 480
Author(s):  
Ponkaj K. Datta ◽  
M. Mujibur Rahman ◽  
Ahmedul Kabir ◽  
M. Mazharul Hoque ◽  
Motlabur Rahman ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Enzyme Linked Immunosorbent Assay ◽  
Rt Pcr ◽  
Igg Antibody ◽  
Antibody Titers ◽  
Qualitative Test ◽  
The Mean ◽  
Randomized Control ◽  
Donor Criteria ◽  
Donor Plasma

Background: Convalescent plasma is considered a promising therapy for severe COVID-19 disease. It is collected from the voluntary donors. Measurement of the antibody titer is necessary before transfusion to predict the outcome in the recipients. Characteristics of the convalescent plasma donors in Bangladesh and their antibody titers are not known.Methods: Convalescent plasma was collected from the voluntary donors who survived the COVID-19 disease to transfuse to the severe COVID-19 patients under a randomized control trial. Total IgG antibody titer was measured in the donor plasma by indirect enzyme-linked immunosorbent assay. Data was collected in a preformed questionnaire before donor plasma collection.Results: The median age is 32 (18-55) years.  Fever, cough, sore throat, diarrhea was most common among 68.3% of the symptomatic participants and the remaining 31.7% were asymptomatic at the time when they were RT-PCR positive. Overall, 57.1% of participants had mild symptoms, 11.1% had moderate symptoms and none had severe symptoms. Participants’ antibody titers were measured 41.68±14.072SD days after the RT-PCR positive date.  Rapid qualitative test could not detect antibody in 11 (17.5%) potential donors. Of the remaining 52 (82.5%) antibody positive participants titer was measured in 43 participants and found 1:320 in 17 (27.0%) (n=63), 1:160 in another 17 (27.0%) (n=63) and 1:80 in rest of the 9 (14.28%) (n=63) Participants. The mean titer of the donors who were hospitalized during their illness (1:274.29) was statistically significantly higher (p=0.043, CI>95%). The mean titer was also higher in female than in male, symptomatic than asymptomatic participants and in donors of A positive blood group. However, these finding are not statistically significant. Antibody titer does not correlate with time of RT-PCR negativity from initial RT-PCR positivity, time from RT-PCR positivity to titer date, age and body mass index.Conclusions: All RT-PCR positive COVID-19 patients subsequently may not develop antibody. Although antibody titer among hospitalized symptomatic patients was significantly higher, further study is needed to recommend optimal convalescent plasma donor criteria. 

scholarly journals Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B

2018 ◽  
Vol 68 (10) ◽  
pp. 1713-1717 ◽  
Author(s):  
Benjamin J Cowling ◽  
Wey Wen Lim ◽  
Ranawaka A P M Perera ◽  
Vicky J Fang ◽  
Gabriel M Leung ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Hemagglutination Inhibition ◽  
Influenza B ◽  
Inhibition Antibody
Sign in / Sign up

Export Citation Format

Share Document